Table 1. Baseline clinical characteristics of infective endocarditis patients according to the tertile of MHR.
| Variables | Tertile 1 (<0.014, n=468) | Tertile 2 (0.014–0.020, n=469) | Tertile 3 (>0.020, n=468) | P |
|---|---|---|---|---|
| Age, mean ± SD, years | 66.20±9.37 | 64.62±10.53 | 64.49±9.66 | 0.013 |
| Male gender, No. (%) | 258 (55.1) | 345 (73.6) | 369 (78.8) | <0.001 |
| Weight, No. (%), kg | 64.14±11.73 | 68.01±11.18 | 67.81±13.03 | <0.001 |
| Heart rate, No. (%), bpm | 74.52±11.14 | 74.41±10.92 | 75.67±10.89 | 0.153 |
| Blood pressure, No. (%), mmHg | ||||
| Systolic | 137.08±18.89 | 135.30±19.04 | 133.99±18.67 | 0.043 |
| Diastolic | 77.11±10.63 | 77.07±11.19 | 76.20±11.06 | 0.357 |
| Heart failure, No. (%) | 56 (12.0) | 51 (10.9) | 63 (13.5) | 0.476 |
| Medical history and risk factors, No. (%) | ||||
| Smoking | 59 (12.6) | 110 (23.5) | 130 (27.8) | <0.001 |
| Myocardial infarction | 64 (13.7) | 78 (16.6) | 105 (22.4) | 0.002 |
| Percutaneous coronary intervention | 108 (23.1) | 111 (23.7) | 103 (22.0) | 0.829 |
| Coronary artery bypass surgery | 10 (2.1) | 9 (1.9) | 6 (1.3) | 0.590 |
| Stroke | 29 (6.2) | 29 (6.2) | 35 (7.5) | 0.658 |
| Atrial fibrillation | 7 (1.5) | 17 (3.6) | 22 (4.7) | 0.020 |
| Hypertension | 361 (77.1) | 364 (77.6) | 354 (75.6) | 0.757 |
| Hyperlipemia | 67 (14.3) | 63 (13.4) | 40 (8.5) | 0.014 |
| In-hospital medication, No. (%) | ||||
| Aspirin | 452 (96.6) | 459 (97.9) | 455 (97.2) | 0.488 |
| P2Y12 | 463 (98.9) | 467 (99.6) | 465 (99.4) | 0.493 |
| Plataal | 18 (3.8) | 11 (2.3) | 18 (3.8) | 0.337 |
| Dual antiplatelet therapy | 449 (95.9) | 457 (97.4) | 452 (96.6) | 0.439 |
| Statin | 455 (97.2) | 460 (98.1) | 462 (98.7) | 0.259 |
| Warfarin | 1 (0.2) | 4 (0.9) | 7 (1.5) | 0.103 |
| ACE inhibitor or ARB | 371 (79.3) | 385 (82.1) | 394 (84.2) | 0.147 |
| CCB | 143 (30.6) | 129 (27.5) | 126 (26.9) | 0.416 |
| Nitroglycerin | 239 (51.1) | 232 (49.5) | 259 (55.3) | 0.177 |
| Beta-blockers | 380 (81.2) | 394 (84.0) | 400 (85.5) | 0.200 |
| Glycoprotein IIb/IIIa inhibitor | 46 (9.8) | 39 (8.3) | 52 (11.1) | 0.353 |
| Laboratory parameters | ||||
| LVEF, mean ± SD, % | 62.08±11.12 | 61.40±10.81 | 58.96±12.39 | <0.001 |
| WBC, mean ± SD, ×109/L | 6.80±1.99 | 7.54±1.70 | 9.01±2.31 | <0.001 |
| Neutrophil, mean ± SD, ×109/L | 4.35±1.80 | 4.72±1.52 | 5.82±2.10 | <0.001 |
| Lymphocyte, mean ± SD, ×109/L | 1.78±0.57 | 1.99±0.68 | 2.09±0.71 | <0.001 |
| Monocyte, mean ± SD, ×109/L | 0.43±0.12 | 0.59±0.11 | 0.83±0.23 | <0.001 |
| Hemoglobin, mean ± SD, g/L | 128.58±17.30 | 131.14±17.33 | 128.88±18.88 | 0.056 |
| PLT, mean ± SD, ×109/L | 213.40±59.01 | 217.92±57.71 | 235.32±74.30 | <0.001 |
| PDW, mean ± SD, fL | 15.49±2.17 | 15.45±2.20 | 15.44±2.21 | 0.944 |
| TG, mean ± SD, mmol/L | 2.01±2.02 | 1.85±1.37 | 1.89±1.35 | 0.275 |
| TC, mean ± SD, mmol/L | 4.77±1.38 | 4.34±1.17 | 4.14±1.05 | <0.001 |
| HDL-C, mean ± SD, mmol/L | 1.11±0.32 | 0.93±0.17 | 0.79±0.16 | <0.001 |
| LDL-C, mean ± SD, mmol/L | 2.74±0.98 | 2.60±0.94 | 2.47±0.86 | <0.001 |
| Serum creatinine, mean ± SD, μmol/L | 97.12±87.65 | 99.74±87.39 | 108.21±77.52 | 0.110 |
| eGFR, mean ± SD, mL/min/1.73 m2 | 80.45±28.42 | 81.53±29.51 | 75.18±29.81 | 0.002 |
| GRACE score, mean ± SD | 128.34±27.35 | 126.67±27.99 | 131.38±28.74 | 0.050 |
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel blocker; LVEF, left ventricular ejection fraction; WBC, white blood cell; PLT, platelet; PDW, platelet distribution width; TG, total triglyceride; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; GRACE, Global Registry of Acute Coronary Events; SD, standard deviation